Balancing the risks and benefits of dual platelet inhibition.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Platelet-Mimicking Nanosponges for Functional Reversal of Antiplatelet Agents.Circulation research · 2023
   Article
2. Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a "real world" STEMI population: results from the Italian "CARDIO-STEMI SANREMO" registry.BMC cardiovascular disorders · 2021
   Observational
3. Temporal Trends of Bleeding Episodes during Half- vs. Standard-Dose Ticagrelor in Acute Coronary Syndrome Patients with Low Platelet Reactivity: A Randomized BLEEDING-ACS Trial.Journal of clinical medicine · 2021
   Article
4. Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors.European heart journal · 2017
   Article
5. Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.Journal of the American Heart Association · 2016
   Article
6. The Tradeoff Between Shorter and Longer Courses of Dual Antiplatelet Therapy After Implantation of Newer Generation Drug-Eluting Stents.Current cardiology reports · 2016
   Review

Corrections and comments

• Comment on
  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.2014
• Comment on
  Long-term use of ticagrelor in patients with prior myocardial infarction.2015

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as